Abbott announced new data from its Phase 3 study of Humira (adalimumab) for the treatment of moderate to severe ulcerative colitis (UC). This study analyzed the subgroup of adult patients (n=494) who had been diagnosed with UC and had not responded well to conventional therapy, such as corticosteroids and/or immunosuppressants. Of the 248 patients treated with Humira, 16.5% achieved clinical remission compared to 9.3% on placebo at Week 8 (P=0.019). At Week 52, 17.3% achieved clinical remission compared to 8.5% on placebo (P=0.004). These results were statistically significant compared to placebo.
Humira, a tumor necrosis factor-alpha blocker, is available as a subcutaneous injection. Humira is indicated for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, chronic plaque psoriasis, and psoriatic arthritis in adults. Humira is also indicated for the treatment of polyarticular juvenile idiopathic arthritis in children ≥4 years of age.
For more information call (800) 633-9110 or visit www.humira.com.